Previous 10 | Next 10 |
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY PR Newswire SYDNEY , July 6, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: K...
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA PR Newswi...
KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT PR Newswire Brain Cancers Forum on Glioblastoma & Diffuse Intrinsic Pontine Glioma Forum SYDNEY , May 25, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: ...
2023-04-14 07:19:13 ET Nasdaq notifies Kazia Therapeutics ( NASDAQ: KZIA ) of regaining compliance with the minimum bid price requirement under Nasdaq listing rule. The company previously received notification from Nasdaq that its American Depository Shares (ADSs) were not in ...
KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT PR Newswire SYDNEY , April 14, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to have received notification from...
KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING PR Newswire SYDNEY , April 4, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation o...
Gainers: OncoSec Medical ( ONCS ) +44% . BioRestorative Therapies BRTX +32% . Astria Therapeutics ( ATXS ) +13% . Certara ( CERT ) +12% . Kazia Therapeutics ( KZIA ) +11% . Losers: ZimVie ( ZIMV ) -45% . Cano Health ( CAN...
Kazia Therapeutics ( NASDAQ: KZIA ) announces a private placement to investors to raise A$4.5M. For further details see: Kazia raises A$4.5M to progress R&D programs
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS PR Newswire SYDNEY , Jan. 16, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotech...
LONDON, UK / ACCESSWRE / December 19, 2022 / Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research center) to investigate the utility of its lead asset, paxalisib (PI3K/mTOR inhibitor) in solid tumors. The col...
News, Short Squeeze, Breakout and More Instantly...
Kazia Therapeutics Limited Company Name:
KZIA Stock Symbol:
NASDAQ Market:
Kazia Therapeutics Limited Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 0.6% to $128.44 on volume of 203,267,889 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 22.1% to $0.5152 on volume of 200,531,827 shares PROSHARES TRUST (SQQQ) fell 0.7% to $7.46 on volume o...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...